


IN THE CLAIMS

Please amend the claims as follows:

Claim 1 (Currently Amended): A pyrrolidine derivative of Formula I:



its a geometrical isomers isomer thereof, its an optically active forms form thereof, as enantiomers an enantiomer thereof, diastereomers a diastereomer thereof, one or more mixtures thereof, ~~of these and its~~ a racemate forms form thereof, ~~as well as~~ or a salt salts thereof, wherein:

R¹ is selected from the group ~~comprising or~~ consisting of H and C₁-C₆-alkyl;

R² is selected from the group ~~comprising or~~ consisting of hydrogen, C₁-C₆-alkyl, C₁-C₆-alkyl aryl, heteroaryl, C₁-C₆-alkyl heteroaryl, C₂-C₆-alkenyl, C₂-C₆-alkenyl aryl, C₂-C₆-alkenyl heteroaryl, C₂-C₆-alkynyl, C₂-C₆-alkynyl aryl, C₂-C₆-alkynyl heteroaryl, C₃-C₈-cycloalkyl, heterocycloalkyl, C₁-C₆-alkyl cycloalkyl, C₁-C₆-alkyl heterocycloalkyl, C₁-C₆-alkyl carboxy, acyl, C₁-C₆-alkyl acyl, C₁-C₆-alkyl acyloxy, C₁-C₆-alkyl alkoxy, alkoxycarbonyl, C₁-C₆-alkyl alkoxycarbonyl, aminocarbonyl, C₁-C₆-alkyl aminocarbonyl, C₁-C₆-alkyl acylamino, C₁-C₆-alkyl ureido, amino, C₁-C₆-alkyl amino, sulfonyloxy, C₁-C₆-alkyl sulfonyloxy, sulfonyl, C₁-C₆-alkyl sulfonyl, sulfinyl, C₁-C₆-alkyl sulfinyl, C₁-C₆-alkyl sulfanyl, and C₁-C₆-alkyl sulfonylamino;

R³ is selected from the group ~~comprising or~~ consisting of aryl and heteroaryl;

X is selected from the group consisting of O ~~[[or]]~~ and NR⁴;

R⁴ is selected from the group ~~comprising or~~ consisting of H, C₁-C₆-alkyl, C₁-C₆-alkyl aryl, C₁-C₆-alkyl heteroaryl, aryl and heteroaryl; ~~[[or]]~~ wherein

R² and R⁴ can form together with the N atom to which they are linked to, a 5-8 membered saturated or unsaturated heterocycloalkyl ring; and
n is an integer from 1 to 3.

Claim 2 (Original): A pyrrolidine derivative according to claim 1, wherein R¹ is methyl.

Claim 3 (Currently Amended): A pyrrolidine derivative according to claim 1 ~~or 2~~, wherein R³ is a phenyl.

Claim 4 (Currently Amended): A pyrrolidine derivative according to ~~any of the preceding claims~~ claim 1, wherein n is an integer 1 or 2.

Claim 5 (Currently Amended): A pyrrolidine derivative according to ~~any of the preceding claims~~ claim 1 wherein R² and R⁴ form together with the N atom to which they are linked, a 5 or 6 membered cycloalkyl or heterocycloalkyl ring[[:]].

Claim 6 (Currently Amended): A pyrrolidine derivative according to ~~claims 1 to 4~~ claim 1 wherein X is O or NH.

Claim 7 (Currently Amended): A pyrrolidine derivative according to ~~any of the preceding claims~~ claim 1, selected from the ~~following~~ group consisting of:

(3EZ,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime;

(3EZ,5S)-1-(1,1'-biphenyl-4-ylcarbonyl)-5-(hydroxymethyl)pyrrolidin-3-one O-methyloxime;

(3E,5S)-1-(1,1'-biphenyl-4-ylcarbonyl)-5-(hydroxymethyl)pyrrolidin-3-one O-methyloxime;

(3Z,5S)-1-(1,1'-biphenyl-4-ylcarbonyl)-5-[(4-methylpiperazin-1-yl)methyl]pyrrolidin-3-one O-methyloxime;

tert-butyl {[(2S,4EZ)-1-(1,1'-biphenyl-4-ylcarbonyl)-4-(methoxyimino)pyrrolidin-2-yl]methoxy} acetate;

{[(2S,4EZ)-1-(1,1'-biphenyl-4-ylcarbonyl)-4-(methoxyimino)pyrrolidin-2-yl]-methoxy} acetic acid;

2- {[(2S,4EZ)-1-(1,1'-biphenyl-4-ylcarbonyl)-4-(methoxyimino)pyrrolidin-2-yl]-methoxy}-N-(2-pyrrolidin-1-ylethyl)acetamide;

(3EZ,5S)-1-(1,1'-biphenyl-4-ylcarbonyl)-5-(methoxymethyl)pyrrolidin-3-one O-methyloxime;

(3EZ, 5S)-1-(1,1'-biphenyl-4-ylcarbonyl)-5-[(4-methylpiperazin-1-yl)methyl]-pyrrolidin-3-one O-methyloxime;

(3EZ,5S)-1-(1,1'-biphenyl-4-ylcarbonyl)-5- {[(4-methoxyphenyl)amino]methyl}-pyrrolidin-3-one O-methyloxime;

(3EZ,5S)-1-(1,1'-biphenyl-4-ylcarbonyl)-5- ({[2-(1H-pyrazol-1-yl)ethyl]amino)-methyl)-pyrrolidin-3-one O-methyloxime;

2- {[(2S,4EZ)-1-(1,1'-biphenyl-4-ylcarbonyl)-4-(methoxyimino)pyrrolidin-2-yl]-methyl}-1H-isoindole-1,3(2H)-dione;

(3EZ,5S)-5-(aminomethyl)-1-(1,1'-biphenyl-4-ylcarbonyl)pyrrolidin-3-one O-methyl-oxime;

N-{[(2S,4EZ)-1-(1,1'-biphenyl-4-ylcarbonyl)-4-(methoxyimino)pyrrolidin-2-yl]methyl}acetamide;

(3EZ,5S)-1-(1,1'-biphenyl-4-ylcarbonyl)-5-(piperidin-1-ylmethyl)pyrrolidin-3-one O-methyloxime; and

(3EZ,5S)-1-(1,1'-biphenyl-4-ylcarbonyl)-5-(2-hydroxyethyl)pyrrolidin-3-one O-methyloxime.

Claim 8 (Currently Amended): ~~A pyrrolidine according to any of the preceding claims for use as a medicament~~ comprising said pyrrolidine derivative according to claim 1.

Claim 9 (Currently Amended): ~~Use of a pyrrolidine derivative according to any of claims 1 to 7 as well as isomers, optically active forms as enantiomers, diastereomers and mixtures of these, as well as salts thereof for the preparation of a medicament for the prevention and/or treatment of~~ A method of treating preterm labor, premature birth or dysmenorrhea, said method comprising administering said pyrrolidine derivative according to claim 1 to a patient in need thereof in an amount sufficient to treat said preterm labor, said premature birth or said dysmenorrhea.


Claim 10 (Currently Amended). ~~Use of a pyrrolidine according to claim 1 to 7, for the preparation of~~ A method of preparing a medicament for the treatment of one or more disorders requiring the modulation of the oxytocin receptor, said method comprising incorporating said pyrrolidine according to claim 1 in said medicament.

Claim 11 (Currently Amended): ~~Use according to claim 10, for the treatment or prevention of disorders~~ A method of treating a disorder associated with the oxytocin receptor activity, said method comprising administering said pyrrolidine derivative according to claim 1 to a patient in need thereof in an amount sufficient to treat said disorder.

Claim 12 (Currently Amended): ~~Use according to claim 10 or 11~~ The method according to claim 10, wherein said modulation consists in the blocking of the oxytocin receptor or in antagonising the binding of oxytocin to ~~its~~ said oxytocin receptor.


Claim 13 (Currently Amended): A pharmaceutical composition ~~containing a~~ comprising said pyrrolidine derivative according to ~~any of claims 1 to 7~~ claim 1 and a pharmaceutically acceptable carrier, diluent or excipient thereof.

Claim 14 (Currently Amended): A process for the preparation of ~~[[a]]~~ said pyrrolidine derivative according to ~~any of claims 1 to 7,~~ claim 1 wherein X is O, comprising ~~the step of an O-alkylation of~~ O-alkylating an alcohol derivatives derivative of formula (II) with an alkylating agent R^2 -LG wherein LG is a leaving group, ~~with R^1 , R^2 , R^3 and n being as defined above.~~



to obtain said pyrrolidine derivative.

Claim 15 (Currently Amended): A process for the preparation of [[a]] said pyrrolidine derivative according to ~~any of claims 1 to 7~~ claim 1 wherein X is NR⁴, comprising ~~the step of~~ a reductively aminating an aldehyde derivative of formula (XI) with an amine HNR²R⁴ wherein R¹, R², R³, R⁴ and n are defined above.



to obtain said pyrrolidine derivative.

Claim 16 (New): The method according to claim 11, wherein said oxytocin receptor activity consists in the blocking of the oxytocin receptor or in antagonising the binding of oxytocin to said oxytocin receptor.